Hamlet BioPharma: Professor to Present Novel Tuberculosis Treatment at Nobel Symposium
Professor Gabriela Godaly, associated with Hamlet BioPharma, will present a new therapeutic concept for tuberculosis at the 178th Nobel Symposium in Chemistry. The presentation focuses on a novel approach to treating pulmonary tuberculosis.
Professor Gabriela Godaly, collaborating with Hamlet BioPharma, is presenting a new therapeutic concept for combating tuberculosis at the 178th Nobel Symposium in Chemistry in Stellenbosch, South Africa. Her presentation, titled "Novel treatment for pulmonary tuberculosis," is scheduled for October 26th.
The treatment concept utilizes a bactericidal peptide, with drug candidates demonstrating potent effects in animal models, according to the company. Tuberculosis remains a leading cause of death globally, and the growing problem of antibiotic resistance significantly impacts treatment options for patients.
The Nobel Symposium in Chemistry is a collaborative initiative focusing on drug discovery and clinical applications, involving Stellenbosch University and other academic partners. The event aims to explore advancements in pharmaceutical research and development.
Godaly is a professor at Lund University. Hamlet BioPharma is a pharmaceutical company developing therapies for cancer and infectious diseases, reporting promising results in both areas.